Genetically engineered antibody analogues and fusion proteins thereof
US6207804A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 18, 1995 |
| Grant date | Mar 27, 2001 |
| Priority date | — |
| Expiry date | Dec 18, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/705
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS). The sites comprise 1) non-covalently associated or disulfide bonded synthetic V.sub.H and V.sub.L dimers, 2) V.sub.H -V.sub.L or V.sub.L -V.sub.H single chains wherein the V.sub.H and V.sub.L are attached by a polypeptide linker, or 3) individual V.sub.H or V.sub.L domains. The binding domains comprise linked CDR and FR regions, which may be derived from separate immunoglobulins. The proteins may also include other polypeptide sequences which function e.g., as an enzyme, toxin, binding site, or site of attachment to an immobilization media or radioactive atom. Methods are disclosed for producing the proteins, for designing BABS having any specificity that can be elicited by in vivo generation of antibody, and for producing analogs thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.